Brianna Briganti, | |
28 Heron Hill Rd, Amston, CT 06231-1648 | |
(603) 391-1359 | |
Not Available |
Full Name | Brianna Briganti |
---|---|
Gender | Female |
Speciality | Behavior Analyst |
Location | 28 Heron Hill Rd, Amston, Connecticut |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1922412956 | NPI | - | NPPES |
110026265E | Medicaid | MA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
101YM0800X | Counselor - Mental Health | (* (Not Available)) | Secondary |
103K00000X | Behavior Analyst | 1-18-29324 (Connecticut) | Primary |
Mailing Address | Practice Location Address |
---|---|
Brianna Briganti, 28 Heron Hill Rd, Amston, CT 06231-1648 Ph: (603) 391-1359 | Brianna Briganti, 28 Heron Hill Rd, Amston, CT 06231-1648 Ph: (603) 391-1359 |
News Archive
Covidien, a leading global provider of healthcare products, today announced CE Mark approval for its EverFlex Self-expanding Peripheral Stent with Entrust Delivery System.
A quarter of patients admitted to Scottish intensive care units have alcohol problems and the majority of those have chronic alcohol disease, with particular problems among men and younger people.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that Scientific American magazine has published in its July issue an article entitled "DNA Drugs Come of Age." The article was co-authored by Dr. David Weiner, Chairman, Scientific Advisory Board, Inovio Pharmaceuticals, and Professor, Department of Pathology & Laboratory Medicine, at the University of Pennsylvania and Dr. Matthew Morrow, a post-doctorate research fellow at University of Pennsylvania.
"Thousands of kidney patients in the United States start dialysis without first being told of kidney transplants that would be cheaper and lead to longer lives, according to a four-month newspaper investigation published Sunday," The Associated Press reports.
Biocept, Inc., a privately-held laboratory testing company focused on the detection, enumeration and analysis of circulating tumor cells (CTCs) in cancer patients, today announced the publication of a paper describing the identification of different CTC phenotypes using its proprietary Cell Enrichment and Extraction platform.
› Verified 7 days ago